Eureka Therapeutics, Inc Revenue
Biotechnology Research • 
Emeryville, California, United States • 21-50 Employees
Eureka Therapeutics, Inc revenue & valuation
| Annual revenue | $9,600,000 |
| Revenue per employee | $205,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $30,800,000 |
| Total funding | $10,600,000 |
Key Contacts at Eureka Therapeutics, Inc
Mei Hong
Senior Director, Intellectual Property
Shaohua Xu Car Immunotherapy
Associate Director, Correlative Studies
Natalie Liu
Director, Investor Relations And Strategic Alliances
Bryan Zimdahl
Senior Director, Clinical Science And Regulatory Affairs
Mingxiao He
Director, Bioprocessing And Manufacturing
Ziyou Cui
Director
Tuck Johnston
Associate Director Qa
Zhiyuan Yang
Director Of Analytics
Wen Fang
Associate Director, Tax And Fp&A
Diana Kay
Senior Director Of Corporate Operations
Company overview
| Headquarters | 5858 Horton Street, Suite 370, Emeryville, CA 94608, US |
| Phone number | +15106547045 |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Oncology, Immunotherapy, Cell Therapy, Phage Display, Therapeutic Antibodies, Cart, Hepatocellular Carcinoma, Engineered T Cell Therapy, Non-Hodgkin'S Lymphoma |
| Founded | 2006 |
| Employees | 21-50 |
| Socials |
Eureka Therapeutics, Inc Email Formats
Eureka Therapeutics, Inc uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@eurekainc.com), used 67.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@eurekainc.com | 67.6% |
{first name}.{last name} | john.doe@eurekainc.com | 32.4% |
About Eureka Therapeutics, Inc
Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer. Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage. Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Eureka Therapeutics, Inc has 20 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Eureka Therapeutics, Inc's funding history, including investment rounds, total capital raised, and key backers.
Eureka Therapeutics, Inc Tech Stack
Discover the technologies and tools that power Eureka Therapeutics, Inc's digital infrastructure, from frameworks to analytics platforms.
Performance
WordPress plugins
JavaScript libraries
Maps
Page builders
JavaScript libraries
Web servers
JavaScript libraries
Programming languages
JavaScript libraries
Blogs
JavaScript graphics
Italy
Canada
France
New ZealandFrequently asked questions
4.8
40,000 users
